Absci Corporation (ABSI)

Absci Inc. ABSI on Thursday collaborated with Oracle Corporation's ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs

World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.

VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:

Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.

Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028

BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications.

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025.

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.

VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci.

VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors.

VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences.